University of North Carolina, Chapel Hill
This is a research study to look at how a new medication compares to standard treatment for reducing acid reflux in patients with Barrett's Esophagus. The study drug is Vonoprazan. This is a pill that is not yet FDA-approved for this purpose in this patient population. The participants will first continue their current acid-reducing medicine (PPI) once a day for at least 7 days. After that, they will have a test to measure acid levels in their esophagus (food tube) while still taking the PPI medication. After this test, they will stop their current PPI medication and start taking the study drug, Vonoprazan, once a day for 7-28 days. They will then have a second acid test while on the study drug (Vonoprazan). Before each test, the participants will complete a short questionnaire about their symptoms. The study team will collect their health history, including medical conditions and current medications. After they finish the study drug, they will have a follow-up visit in about 30 days. The participation in the study will then end.
This is a prospective open-label study of PCAB in adults aged 18 years or older with nondysplastic Barrett's esophagus (NDBE) on maintenance PPI therapy. At the time of enrollment, participants will continue their usual PPI (any brand), standardized to once daily dosing for at least 7 days. After ≥7 days on once daily dosing, participants will undergo ambulatory 24-hour pH impedance testing without interruption of PPI therapy. After pH testing is complete, PPIs will be discontinued and replaced with vonoprazan 20 mg once daily for 7-28 days. After ≥7 days, 24-hour pH impedance testing will be…
Inclusion Criteria: * Adults aged 18 or older at time of consent. * Able to read and understand English and provide written informed consent. * History of Gastroesophageal Reflux Disease (GERD) with or without heartburn. * Diagnosed with nondysplastic Barrett's Esophagus (NBDE) defined as meeting the following within the past 3 years: * Endoscopically confirmed BE with segment length ≥2 cm (to avoid those with an irregular Z line), and * Histologic evidence of intestinal metaplasia without dysplasia ("dysplasia" includes indefinite for dysplasia). * Currently on proton pump inhibitor (PP…
Potassium -competitive acid blockers (PCABs) are a newer class of acid-suppressing medications more potent than PPIs, with a faster onset and longer duration of action. PCABs are FDA-approved.
Arctuva estimate
Verify or correct the compensation shown for this listing.